Developer docs
API playgroundTry for free, no card

Search company profiles

Cimedical

Full company profile

uuid00265za

Namestring
Cimedical
Legal namestring
CENTRO DE INVESTIGACIÓN MEDICO ASISTENCIAL SAS
Websiteurl
cimedical.co
Company typeenum
Private
Founded yearint
1993
Descriptiontext

Cimedical (legal name Centro de Investigación Médico Asistencial SAS) is a Barranquilla, Colombia-based clinical research organization and healthcare services provider (Institución Prestadora de Servicios, IPS) operating from a single site since 1993 and active in industry-sponsored clinical research since 2007. Its core offerings span Phase I-IV interventional trials, observational studies, and bioavailability/bioequivalence studies executed on behalf of pharmaceutical sponsors and CROs; a parallel patient-care practice delivering rheumatology, internal medicine, orthopedics, dermatology, and telemedicine services; and an independent Research Ethics Committee (CEI) that audits, trains, and reviews protocols for the site and external clients. The product layer is anchored by CIMA 2.0, a proprietary in-house electronic medical record and clinical history platform, complemented by a 100% digital Ethics Committee review portal; both are partially funded by a 190 million COP ICONOS grant from the Atlántico Governorate and ACOPI.

Cimedical runs its own hospitalization infrastructure (over 500 m2, 26 beds across 3 rooms) dedicated in part to bioequivalence work, and has accumulated 36 registered clinical trials covering rheumatology, nephrology, cardiology, dermatology, pulmonology, immunology, and infectious diseases including lupus, rheumatoid arthritis, asthma, and dengue. The model is sales-led and professional-services-based: revenue is generated through per-contract engagements with sponsors such as AstraZeneca, Pfizer, Novartis, Roche, Janssen, Biogen, Sanofi, GSK, Amgen, and AbbVie, routed via global CRO partners including IQVIA, PPD, PRA Health Sciences, Worldwide Clinical Trials, and ICON, plus direct bioequivalence engagements with manufacturers such as PROCAPS SA. The site is INVIMA-certified in Good Clinical Practices (May 2025) and Good Bioavailability/Bioequivalence Practices, and is registered with the US Office for Human Research Protections (OHRP-IRB).

The differentiation rests on regulatory certifications, a specialized multi-therapeutic investigator team with over 20 years of research experience, dedicated bioequivalence infrastructure, and an in-house digital platform stack, all concentrated in a single regional market on Colombia's Caribbean coast. As of January 2026 the organization added an inaugural Chief AI Officer role (Dr. Adil Haider), but no AI products, models, or revenue from AI-enabled services have been disclosed.

Short descriptiontext

Cimedical is a Barranquilla-based clinical research organization and healthcare provider conducting Phase I-IV trials, bioequivalence studies, and patient care in rheumatology and chronic disease for global pharma sponsors and CROs such as IQVIA, PPD, and Novartis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBarranquilla, Colombia
HQ citystring
Barranquilla
HQ countrystring
Colombia
HQ regionstring
Latin America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical research services, bioequivalence studies, clinical trial site, healthcare assistance services, ethics committee services
Industry1 code
PRIMARYHLACAMAA
Clinical Laboratory LIS (Core Lab/Hospital Lab)
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
NAICS code1 code
  • General Medical and Surgical Hospitals62211
SIC code3 codes
  • Services-Offices & Clinics Of Doctors Of Medicine8011
  • Services-Specialty Outpatient Facilities, Nec8093
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Research Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Clinical Trial Services
TypeProfessional Services
Description

Revenue generated from conducting Phase I-IV interventional clinical trials and observational studies for pharmaceutical companies. Services include protocol development, clinical stage execution, bioanalytical services, biostatistical analysis, and final reporting.

cimedical.co
2Bioavailability and Bioequivalence Studies
TypeProfessional Services
Description

Specialized studies to establish bioequivalence of pharmaceutical products against reference products for regulatory approval. Covers full study lifecycle from protocol development through clinical and bioanalytical phases to final reporting.

cimedical.co
3Healthcare/Assistance Services
TypeProfessional Services
Description

Primary and specialized healthcare services including rheumatology, internal medicine, orthopedics, physiotherapy, laboratory tests, densitometry, infusion room, vaccination, and telemedicine services.

cimedical.co
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 record
1CIMA 2.0
Description

Electronic clinical history platform developed by Cimedical for medical records management.

cimedical.co
Core offering1 text field

Cimedical is a clinical research center and healthcare services provider in Barranquilla, Colombia, offering Phase I-IV interventional clinical trials, observational studies, bioavailability/bioequivalence studies, and patient care services. The company operates its proprietary CIMA 2.0 electronic clinical history platform to support research data management, while serving pharmaceutical sponsors and CROs alongside individual patients requiring specialized care.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Top Recruiter in Colombia to the PRO2TECT program from AKEBIA
+3 more records
Product overview1 text field

Cimedical is a medical research and healthcare institution (IPS) offering a unified platform of clinical research services and electronic health records. The core offering centers on CIMA 2.0, its electronic medical record platform, complemented by the CIMA Portal for system access. Services span interventional and observational clinical trials, bioavailability/bioequivalence studies, healthcare/patient care, and ethics committee services. The institution operates clinical studies across multiple therapeutic areas including rheumatology, cardiology, dermatology, nephrology, pneumology, and infectious diseases, with a focus on autoimmune diseases and chronic conditions.

Product and service1 record
1Interventional Clinical Studies Services
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership22 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmaceutical company partnership for clinical trial sponsorship. Cimedical has conducted AstraZeneca-sponsored studies including Asthma Severa study (2018). AstraZeneca is listed among the pharmaceutical allies on the clinical studies page.

2Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmaceutical company partnership for clinical trial sponsorship including Insuficiencia Cardíaca study (2017). Listed as pharmaceutical ally for clinical research.

cimedical.co
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmaceutical company partnership for clinical trials including Covid-19 (2020) and Dengue (2023) studies. Listed as pharmaceutical ally with multiple study engagements.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing pharmaceutical partnership including multiple studies in Espondilitis Anquilosante (2018, 2020), Artritis Reumatoide (2012), Psoriasis (2012), and Urticaria (2022).

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmaceutical partnership for clinical trials including Prevalencia A Insuficiencia Cardíaca study (2019) and Artritis Reumatoide studies (2010, 2013).

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmaceutical partnership for clinical trial sponsorship including Artritis Reumatoide study (2012).

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmaceutical partnership including Dermatitis Atópica study (2019) under Sanofi Aventis brand.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing partnership for multiple lupus and nephritis studies (Nefritis Lúpica 2012, 2014; Lupus Eritematoso Sistémico 2018).

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Global CRO partnership. Awarded 'Achievement of Excellence 2017' recognition. IQVIA is listed as CRO ally providing regulatory and research support.

10PPD
Strategic tierCoreTypeStrategic or Co-development Partner
Description

CRO partnership for clinical trial support. PPD is listed among CRO allies on the clinical studies page.

11PRA Health Sciences
Strategic tierCoreTypeStrategic or Co-development Partner
Description

CRO partnership for clinical trial operations. Listed among CRO allies on the clinical studies page.

cimedical.co
Strategic tierCoreTypeStrategic or Co-development Partner
Description

CRO partnership for clinical trial support. Listed among CRO allies on the clinical studies page.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmaceutical partnership listed among allies on the clinical studies page.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmaceutical partnership for Osteoporosis studies (2013, 2015). Listed among pharmaceutical allies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmaceutical partnership for Lupus Eritematoso Sistémico (2012) and Artritis Reumatoide (2020) studies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmaceutical partnership listed among allies on the clinical studies page.

17PROCAPS SA
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Bioequivalence study sponsorship for Metformina 1000mg tablet study (2018). PROCAPS is a Colombian pharmaceutical company.

cimedical.co
18OHRP-IRBS-IRB
Strategic tierCoreTypeStrategic or Co-development Partner
Description

US Office for Human Research Protections registration providing international backing for research ethics standards. Cimedical maintains active international partnerships through this IRB registration.

cimedical.co
19ICON
Strategic tierMinorTypeStrategic or Co-development Partner
Description

CRO partner listed among allies on the clinical studies page.

cimedical.co
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Pharmaceutical company partner for bioequivalence studies, featured on the bioequivalence page.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Government partner that co-funded the CIMA 2.0 platform development through the ICONOS grant program along with ACOPI.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Business association partner providing co-funding for innovation through the ICONOS grant program with the Atlántico Governorate.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Worldwide Clinical Trials is a global CRO listed as one of Cimedical's CRO allies. It provides Phase I-IV clinical trial services with strong capabilities in bioequivalence and early-phase work—directly overlapping with Cimedical's core offerings.

TypeBroad incumbent
Description

IQVIA is the world's largest CRO and is both a Cimedical partner (CIMEDICAL has worked with IQVIA/QuintilesIMS for years) and a competitor. IQVIA operates site services globally and provides direct comparator to Cimedical's clinical trial and bioequivalence services, though at vastly larger scale.

TypeBroad incumbent
Description

PPD is one of Cimedical's listed CRO partners and a major global CRO now owned by Thermo Fisher Scientific. PPD operates across all clinical phases and competes with Cimedical for outsourced clinical trial execution in Latin America.

TypeEmerging player
Description

Clinipace Worldwide is a mid-sized CRO focused on emerging biopharma and adaptive clinical trial design. Comparable to Cimedical as a contract clinical research services provider, though more technology-enabled and serving a broader client mix.

TypeBroad incumbent
Description

ICON plc is a global CRO that acquired PRA Health Sciences and is listed as one of Cimedical's CRO partners. ICON runs Phase I-IV trials globally and competes with Cimedical for pharma-sponsored Latin American trial placements.

TypeBroad incumbent
Description

Medpace is a mid-to-large global CRO providing full-service Phase I-IV clinical trial management. Medpace operates across Latin America and competes with Cimedical for pharma-sponsored trial placement, though at meaningfully larger scale.

TypeBroad incumbent
Description

Charles River Laboratories provides early-stage CRO services, bioequivalence/biopharmaceutics research, and safety assessment. Comparable to Cimedical in the bioequivalence and bioanalytical dimension, though serving a global client base across multiple geographies.

TypeBroad incumbent
Description

Parexel is a major global CRO offering Phase I-IV clinical trial services and biopharmaceutical solutions. Comparable to Cimedical in core clinical trial execution but operating globally at much larger scale, with established Latin American site network capabilities.

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers12 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cimedical

Clinical Research Servicescimedical.co

Cimedical is a Barranquilla-based clinical research organization and healthcare provider conducting Phase I-IV trials, bioequivalence studies, and patient care in rheumatology and chronic disease for global pharma sponsors and CROs such as IQVIA, PPD, and Novartis.

What Cimedical does

Cimedical (legal name Centro de Investigación Médico Asistencial SAS) is a Barranquilla, Colombia-based clinical research organization and healthcare services provider (Institución Prestadora de Servicios, IPS) operating from a single site since 1993 and active in industry-sponsored clinical research since 2007. Its core offerings span Phase I-IV interventional trials, observational studies, and bioavailability/bioequivalence studies executed on behalf of pharmaceutical sponsors and CROs; a parallel patient-care practice delivering rheumatology, internal medicine, orthopedics, dermatology, and telemedicine services; and an independent Research Ethics Committee (CEI) that audits, trains, and reviews protocols for the site and external clients. The product layer is anchored by CIMA 2.0, a proprietary in-house electronic medical record and clinical history platform, complemented by a 100% digital Ethics Committee review portal; both are partially funded by a 190 million COP ICONOS grant from the Atlántico Governorate and ACOPI.

Cimedical runs its own hospitalization infrastructure (over 500 m2, 26 beds across 3 rooms) dedicated in part to bioequivalence work, and has accumulated 36 registered clinical trials covering rheumatology, nephrology, cardiology, dermatology, pulmonology, immunology, and infectious diseases including lupus, rheumatoid arthritis, asthma, and dengue. The model is sales-led and professional-services-based: revenue is generated through per-contract engagements with sponsors such as AstraZeneca, Pfizer, Novartis, Roche, Janssen, Biogen, Sanofi, GSK, Amgen, and AbbVie, routed via global CRO partners including IQVIA, PPD, PRA Health Sciences, Worldwide Clinical Trials, and ICON, plus direct bioequivalence engagements with manufacturers such as PROCAPS SA. The site is INVIMA-certified in Good Clinical Practices (May 2025) and Good Bioavailability/Bioequivalence Practices, and is registered with the US Office for Human Research Protections (OHRP-IRB).

The differentiation rests on regulatory certifications, a specialized multi-therapeutic investigator team with over 20 years of research experience, dedicated bioequivalence infrastructure, and an in-house digital platform stack, all concentrated in a single regional market on Colombia's Caribbean coast. As of January 2026 the organization added an inaugural Chief AI Officer role (Dr. Adil Haider), but no AI products, models, or revenue from AI-enabled services have been disclosed.

Cimedical firmographics

Firmographics
Name
Cimedical
Legal name
CENTRO DE INVESTIGACIÓN MEDICO ASISTENCIAL SAS
Website
https://cimedical.co
Company type
Private
Founded year
1993
Operating status
Operating
Headcount range
11–50 employees
Short description
Cimedical is a Barranquilla-based clinical research organization and healthcare provider conducting Phase I-IV trials, bioequivalence studies, and patient care in rheumatology and chronic disease for global pharma sponsors and CROs such as IQVIA, PPD, and Novartis.
Ownership category
akta.pro rank

Cimedical industry classification

Industry
Product category
Clinical Research Services
NAICS
General Medical and Surgical Hospitals (62211)
SIC
Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLACAMAA
Clinical Laboratory LIS (Core Lab/Hospital Lab)
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics

Keywords

  • Clinical research services
  • Bioequivalence studies
  • Clinical trial site
  • Healthcare assistance services
  • Ethics committee services

Where Cimedical is headquartered

Location

Headquarters

HQ city
Barranquilla
HQ country
Colombia
HQ region
Latin America

Offices3 records

Markets served

Cimedical business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

  1. Clinical Trial Services: Revenue generated from conducting Phase I-IV interventional clinical trials and observational studies for pharmaceutical companies. Services include protocol development, clinical stage execution, bioanalytical services, biostatistical analysis, and final reporting.
  2. Bioavailability and Bioequivalence Studies: Specialized studies to establish bioequivalence of pharmaceutical products against reference products for regulatory approval. Covers full study lifecycle from protocol development through clinical and bioanalytical phases to final reporting.
  3. Healthcare/Assistance Services: Primary and specialized healthcare services including rheumatology, internal medicine, orthopedics, physiotherapy, laboratory tests, densitometry, infusion room, vaccination, and telemedicine services.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Cimedical product offering

Product offering

Core offering

Cimedical is a clinical research center and healthcare services provider in Barranquilla, Colombia, offering Phase I-IV interventional clinical trials, observational studies, bioavailability/bioequivalence studies, and patient care services. The company operates its proprietary CIMA 2.0 electronic clinical history platform to support research data management, while serving pharmaceutical sponsors and CROs alongside individual patients requiring specialized care.

Product overview

Cimedical is a medical research and healthcare institution (IPS) offering a unified platform of clinical research services and electronic health records. The core offering centers on CIMA 2.0, its electronic medical record platform, complemented by the CIMA Portal for system access. Services span interventional and observational clinical trials, bioavailability/bioequivalence studies, healthcare/patient care, and ethics committee services. The institution operates clinical studies across multiple therapeutic areas including rheumatology, cardiology, dermatology, nephrology, pneumology, and infectious diseases, with a focus on autoimmune diseases and chronic conditions.

Differentiator

Problem solved

Functional benefit

Brands

  • CIMA 2.0: Electronic clinical history platform developed by Cimedical for medical records management.

Products and services

  • Interventional Clinical Studies Services

Quantifiable outcome

  • Top Recruiter in Colombia to the PRO2TECT program from AKEBIA
  • +3 more outcomes

Companies that use Cimedical

Customer profile

Named customers12 records

Segments3 records

Ideal customer profiles2 records

Cimedical technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Cimedical partnerships and signals

Strategic signal

Partnerships

22 partnerships are on record, tiered core and minor.

  • AstraZenecacoreStrategic or Co-development PartnerPharmaceutical company partnership for clinical trial sponsorship. Cimedical has conducted AstraZeneca-sponsored studies including Asthma Severa study (2018). AstraZeneca is listed among the pharmaceutical allies on the clinical studies page.
  • Boehringer IngelheimcoreStrategic or Co-development PartnerPharmaceutical company partnership for clinical trial sponsorship including Insuficiencia Cardíaca study (2017). Listed as pharmaceutical ally for clinical research.
  • JanssencoreStrategic or Co-development PartnerPharmaceutical company partnership for clinical trials including Covid-19 (2020) and Dengue (2023) studies. Listed as pharmaceutical ally with multiple study engagements.
  • NovartiscoreStrategic or Co-development PartnerLong-standing pharmaceutical partnership including multiple studies in Espondilitis Anquilosante (2018, 2020), Artritis Reumatoide (2012), Psoriasis (2012), and Urticaria (2022).
  • PfizercoreStrategic or Co-development PartnerPharmaceutical partnership for clinical trials including Prevalencia A Insuficiencia Cardíaca study (2019) and Artritis Reumatoide studies (2010, 2013).
  • RochecoreStrategic or Co-development PartnerPharmaceutical partnership for clinical trial sponsorship including Artritis Reumatoide study (2012).
  • SanoficoreStrategic or Co-development PartnerPharmaceutical partnership including Dermatitis Atópica study (2019) under Sanofi Aventis brand.
  • BiogencoreStrategic or Co-development PartnerLong-standing partnership for multiple lupus and nephritis studies (Nefritis Lúpica 2012, 2014; Lupus Eritematoso Sistémico 2018).
  • IQVIA (QuintilesIMS)coreStrategic or Co-development PartnerGlobal CRO partnership. Awarded 'Achievement of Excellence 2017' recognition. IQVIA is listed as CRO ally providing regulatory and research support.
  • PPDcoreStrategic or Co-development PartnerCRO partnership for clinical trial support. PPD is listed among CRO allies on the clinical studies page.
  • PRA Health SciencescoreStrategic or Co-development PartnerCRO partnership for clinical trial operations. Listed among CRO allies on the clinical studies page.
  • Worldwide Clinical TrialscoreStrategic or Co-development PartnerCRO partnership for clinical trial support. Listed among CRO allies on the clinical studies page.
  • AbbViecoreStrategic or Co-development PartnerPharmaceutical partnership listed among allies on the clinical studies page.
  • AmgencoreStrategic or Co-development PartnerPharmaceutical partnership for Osteoporosis studies (2013, 2015). Listed among pharmaceutical allies.
  • GlaxoSmithKline (GSK)coreStrategic or Co-development PartnerPharmaceutical partnership for Lupus Eritematoso Sistémico (2012) and Artritis Reumatoide (2020) studies.
  • MerckcoreStrategic or Co-development PartnerPharmaceutical partnership listed among allies on the clinical studies page.
  • PROCAPS SAcoreStrategic or Co-development PartnerBioequivalence study sponsorship for Metformina 1000mg tablet study (2018). PROCAPS is a Colombian pharmaceutical company.
  • OHRP-IRBS-IRBcoreStrategic or Co-development PartnerUS Office for Human Research Protections registration providing international backing for research ethics standards. Cimedical maintains active international partnerships through this IRB registration.
  • ICONminorStrategic or Co-development PartnerCRO partner listed among allies on the clinical studies page.
  • PharmascienceminorStrategic or Co-development PartnerPharmaceutical company partner for bioequivalence studies, featured on the bioequivalence page.
  • Gobernación del AtlánticocoreGTM or Marketing PartnerGovernment partner that co-funded the CIMA 2.0 platform development through the ICONOS grant program along with ACOPI.
  • ACOPIcoreGTM or Marketing PartnerBusiness association partner providing co-funding for innovation through the ICONOS grant program with the Atlántico Governorate.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Cimedical competitors and assessment

Company assessment

Direct peers

  • Worldwide Clinical Trials: Worldwide Clinical Trials is a global CRO listed as one of Cimedical's CRO allies. It provides Phase I-IV clinical trial services with strong capabilities in bioequivalence and early-phase work—directly overlapping with Cimedical's core offerings.

Broad incumbents

  • IQVIA: IQVIA is the world's largest CRO and is both a Cimedical partner (CIMEDICAL has worked with IQVIA/QuintilesIMS for years) and a competitor. IQVIA operates site services globally and provides direct comparator to Cimedical's clinical trial and bioequivalence services, though at vastly larger scale.
  • PPD (Thermo Fisher Scientific): PPD is one of Cimedical's listed CRO partners and a major global CRO now owned by Thermo Fisher Scientific. PPD operates across all clinical phases and competes with Cimedical for outsourced clinical trial execution in Latin America.
  • ICON plc: ICON plc is a global CRO that acquired PRA Health Sciences and is listed as one of Cimedical's CRO partners. ICON runs Phase I-IV trials globally and competes with Cimedical for pharma-sponsored Latin American trial placements.
  • Medpace: Medpace is a mid-to-large global CRO providing full-service Phase I-IV clinical trial management. Medpace operates across Latin America and competes with Cimedical for pharma-sponsored trial placement, though at meaningfully larger scale.
  • Charles River Laboratories: Charles River Laboratories provides early-stage CRO services, bioequivalence/biopharmaceutics research, and safety assessment. Comparable to Cimedical in the bioequivalence and bioanalytical dimension, though serving a global client base across multiple geographies.
  • Parexel International: Parexel is a major global CRO offering Phase I-IV clinical trial services and biopharmaceutical solutions. Comparable to Cimedical in core clinical trial execution but operating globally at much larger scale, with established Latin American site network capabilities.

Emerging players

  • Clinipace Worldwide: Clinipace Worldwide is a mid-sized CRO focused on emerging biopharma and adaptive clinical trial design. Comparable to Cimedical as a contract clinical research services provider, though more technology-enabled and serving a broader client mix.

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Cimedical social profiles

Digital presence

Cimedical compliance and trust

Trust signal

Compliance7 records

Cimedical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cimedical leadership team

Management profile

Number of profiles

Profiles1 record

Cimedical funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cimedical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cimedical

What does Cimedical do?

Cimedical is a clinical research center and healthcare services provider in Barranquilla, Colombia, offering Phase I-IV interventional clinical trials, observational studies, bioavailability/bioequivalence studies, and patient care services. The company operates its proprietary CIMA 2.0 electronic clinical history platform to support research data management, while serving pharmaceutical sponsors and CROs alongside individual patients requiring specialized care.

Is Cimedical a public or private company?

Cimedical is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Cimedical founded?

Cimedical was founded in 1993. It employs 11 to 50 people.

Where is Cimedical based?

Cimedical is headquartered in Barranquilla, Colombia, in the Latin America region.

How does Cimedical make money?

Three revenue lines are on record. Clinical Trial Services are the primary driver. The others are bioavailability and Bioequivalence Studies and healthcare/Assistance Services.

Who are Cimedical's main competitors?

Worldwide Clinical Trials is listed as a direct peer. Broad incumbents are IQVIA, PPD (Thermo Fisher Scientific), ICON plc, Medpace, Charles River Laboratories and Parexel International. Clinipace Worldwide is listed as an emerging player.

Does Cimedical have an API?

No public API is recorded for Cimedical.

What industry is Cimedical in?

Cimedical's product category is Clinical Research Services. Its primary akta.pro industry code is HLACAMAA, Clinical Laboratory LIS (Core Lab/Hospital Lab). Its NAICS code is 62211 and its SIC code is 8011.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales